Dalmau J, Vicens B, Zapatero J, Bruseghini L
Arzneimittelforschung. 1981;31(10a):1845-9.
Tolerance of N-2-(p-chlorophenoxy)-isobutyryl-N'-morpholinomethylurea (plafibride, ITA 104) administered over a 3-month period was studied in a group of healthy volunteers. Acetylsalicylic acid (ASA) was used as a reference drug. Both drugs were administered p.o. at the dose of 1600 mg/d. Plafibride showed a platelet antiaggregant effect similar in intensity to that shown by ASA, but its gastrointestinal tolerance was better. In the same way, plafibride showed a hypolipemic effect which was characterized by a decrease in the plasma level of total lipids and triglycerides and also by a drop in the percentage of the pre-beta-fraction of the lipoproteinogram at the expense of an increase in the alpha-fraction. No rebound effect was noticed when administration of the drug was stopped. The tolerance of plafibride was very good, both from the clinical and analytical point of view.
在一组健康志愿者中研究了连续3个月服用N-2-(对氯苯氧基)-异丁酰基-N'-吗啉甲基脲（普拉贝特，ITA 104）的耐受性。乙酰水杨酸（ASA）用作参比药物。两种药物均口服给药，剂量为1600 mg/d。普拉贝特显示出与ASA相似强度的血小板抗聚集作用，但其胃肠道耐受性更好。同样，普拉贝特显示出降血脂作用，其特征是血浆总脂质和甘油三酯水平降低，脂蛋白电泳前β-组分百分比下降，同时α-组分增加。停药时未观察到反跳效应。从临床和分析角度来看，普拉贝特的耐受性都非常好。
